EUVIMEDEUVIMED entdecken
Crossref

Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer

Emanuele Vita iD, Federico Monaca, Domenico Milardi, Luca Mastrantoni, Alessio Stefani, Edoardo Vergani, Jacopo Russo, Diletta Barone, Ileana Sparagna, Antonio Vitale iD, Alessandro Scala, Denis Occhipinti und 4 weitere

Cancer · 2024

DOI: 10.1002/cncr.35293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Emanuele Vita und 15 weiteren Autor:innen. Beteiligte Einrichtung: UOSD Oncologia Toraco-Polmonare, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro C…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Anaplastic Lymphoma Kinase, Lung Neoplasms, Carbazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is reported that treatment with anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) induces hypogonadism both in male patients with ALK‐positive cancer and in murine models.

Methods

In this study, three groups, including an experimental group of male patients with ALK‐positive, advanced non–small cell lung cancer (ANSCLC) who were receiving alectinib (cohort A), a control group of female patients with ALK‐positive ANSCLC who were receiving alectinib (cohort B), and a control group of male patients with ALK‐negative ANSCLC (cohort C), prospectively underwent a full hormone assessment for androgen deficiency at 8 weeks after the start of treatment and in case of reported suspected symptoms. Patients with major sexual dysfunctions were referred to an endocrinologist.

Results

Ninety‐five patients were consecutively enrolled onto the study. Among sixty‐eight male patients, both median total testosterone levels (2.93 vs. 4.92 ng/ml; p = .0001) and free testosterone levels (0.11 vs. 0.17 pg/ml; p = .0002) were significantly lower in ALK‐positive ANSCLC patients in cohort A compared with ALK‐negative patients in cohort C; conversely, median FSH (10.32 vs. 17.52 mUI/ml; p = .0059) and LH levels (4.72 vs. 7.49 mUI/ml; p = .0131) were significantly higher in cohort C compared to cohort A. Median inhibin B levels were higher in ALK‐positive male patients (74.3 vs. 44.24 pg/ml; p = .0038), but all patients had inhibin B values within the normal range. The percentage of male patients who had positive scores on the Androgen Deficiency in Aging Males (ADAM) questionnaire was 62% in cohort A and 26.8% in cohort C, including eight patients who reported at least one major symptom and were referred to Andrology Unit. No significant differences in the endocrine assessment were reported between cohorts A and B.

Conclusions

Symptoms of androgen deficiency should be tracked in male patients with ALK‐positive ANSCLC who are receiving alectinib, and testosterone replacement should be considered, as appropriate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAnaplastic Lymphoma KinaseLung NeoplasmsCarbazolesPiperidinesTestosteroneHumansMaleMiddle AgedAgedAdultProtein Kinase InhibitorsSexual Dysfunction, PhysiologicalFemaleAndrogensProspective StudiesHypogonadismReceptor Protein-Tyrosine Kinases

Stichwörter der Autor:innen

alectinibanaplastic lymphoma kinase (ALK)hypogonadismnon–small cell lung cancer (NSCLC)

Substanzen

alectinibAnaplastic Lymphoma KinaseALK protein, humanCarbazolesPiperidinesTestosteroneProtein Kinase InhibitorsAndrogensReceptor Protein-Tyrosine Kinases

Autor:innen und Institutionen

  • UOSD Oncologia Toraco-Polmonare, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • UOC Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
  • UOC di Medicina Interna, Endocrinologia e Diabetologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

ORCID-Profile: Emanuele Vita, Antonio Vitale, Emilio Bria

Förderung

  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Vita, E., Monaca, F., Milardi, D., Mastrantoni, L., Stefani, A., Vergani, E., Russo, J., Barone, D., Sparagna, I., Vitale, A., Scala, A., Occhipinti, D., Di Salvatore, M., Pontecorvi, A., Tortora, G., & Bria, E. (2024). Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.35293

Vancouver

Vita E, Monaca F, Milardi D, Mastrantoni L, Stefani A, Vergani E, et al. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer. Cancer. 2024. doi:10.1002/cncr.35293

BibTeX
@article{Vita2024,
  author = {Vita, Emanuele and Monaca, Federico and Milardi, Domenico and Mastrantoni, Luca and Stefani, Alessio and Vergani, Edoardo and Russo, Jacopo and Barone, Diletta and Sparagna, Ileana and Vitale, Antonio and Scala, Alessandro and Occhipinti, Denis and Di Salvatore, Mariantonietta and Pontecorvi, Alfredo and Tortora, Giampaolo and Bria, Emilio},
  title = {Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35293}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche